The 5 Most Interesting Analyst Questions From Progyny’s Q2 Earnings Call

Progyny (PGNY) reported Q2 revenue of $350.5M vs $348.5M estimates and adjusted EPS of $0.55 vs $0.52, with adjusted EBITDA of $62.1M. Management cited employer demand, retention, and seasonality for sales volumes. Full-year revenue guidance was cut to $1.37B midpoint and EBITDA to $236.5M. Analysts asked about seasonality, demand, utilization forecasting, and expansion.

Original reporting
Published Aug 13, 2026, 8:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:42 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The 5 Most Interesting Analyst Questions From Progyny’s Q2 Earnings Call — source image
Decision brief

The 30-second read

$PGNYBearishMed
01

Why it matters

Despite revenue and non-GAAP profit beating estimates, management lowered full-year revenue and EBITDA midpoints. Analyst Q&A focused on whether flat sales volumes reflect demand softness versus prudent guidance, and whether seasonality is confined to specific cohorts or regions.

02

Market read

Traders should focus on the guidance reset and the market’s interpretation of whether seasonality is temporary versus a demand issue, since the article provides concrete midpoint numbers and management framing.

03

What to watch

The article emphasizes improved forecasting algorithms and margin expansion, which could offset volume softness if utilization rebounds faster than the market expects.

Relevance 7/10Novelty 6/10Timing: post-Q2 earnings call, pre-next-quarter setup

Background

The piece summarizes Progyny’s Q2 CY2026 earnings call, highlighting analyst questions on seasonality, utilization forecasting, and growth opportunities.

Company-level read

Ticker impact

$PGNYBearishMedium confidence
Context

Progyny guided full-year revenue down to $1.37B midpoint and EBITDA to $236.5M, after Q2 beats but negative market reaction.

Expected impact

Near-term downside bias versus prior expectations, with volatility around whether engagement rebounds as seasonality fades.

Evidence & confidence

The article discloses a specific guidance reduction (revenue and EBITDA midpoints) plus management explanations that softness is broad-based and seasonal, which can keep sentiment pressured until utilization and engagement normalize.

Market effects

Managed women’s health and fertility services demand appears resilient, but seasonality and utilization visibility remain key swing factors for earnings quality.

No specific regional shock; management says softness is broad-based and not tied to a particular cohort or region.

International expansion is discussed as secondary to U.S. growth, limiting immediate global read-through.

Counterpoint

If the guidance cut is primarily seasonal and early client commitments are ahead of last year, the selloff may be overdone and could reverse as engagement normalizes.

Key entities

  • Progyny

    Subject of the article; Q2 results, guidance reduction, and management commentary on seasonality and utilization visibility.

  • Peter Anevski

    CEO quoted on early client commitments, forecasting predictability, and growth focus (U.S. and multinational clients with U.S. HQ).

  • Mark S. Livingston

    CFO quoted on margin maintenance, investment capacity, and broad-based nature of seasonality softness.

Related articles

$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.

$PGNYHigh

This fertility benefit business is set to boom. Buy the stock now, Wells Fargo says

Wells Fargo initiated coverage of Progyny with an overweight rating and $37 price target, implying 45% upside. The analyst cited demographic trends, corporate wellness focus, and healthcare innovation as drivers. Progyny's market share growth, global expansion, and new offerings were highlighted. Nine of 11 analysts rate the stock a buy or strong buy, with shares up 13% over the past year.

$PGNYMedAI 8/10

Progyny (PGNY) Q2 2026 Earnings Call Transcript

Progyny (PGNY) reported Q2 2026 revenue of $350.5 million, up 5.3% reported (11% excluding a transition agreement), and net income of $28.1 million ($0.34/diluted share). Adjusted EBITDA rose to $62.1 million, with gross margin expanding to 25.5%. Fertility benefit revenue was $230.2 million. Full-year 2026 guidance: revenue $1.36B to $1.385B, adjusted EBITDA $233M to $240M.

$PGNYMedAI 8/10

Progyny (PGNY) Q2 2026 Earnings Call Transcript

Progyny (PGNY) reported Q2 2026 revenue of $350.5M (+5.3% reported, +11% excluding a transition agreement), net income of $28.1M ($0.34/share), and adjusted EBITDA of $62.1M (17.7% margin). Fertility benefit revenue was $230.2M and pharmacy $120.3M. Guidance: 2026 revenue $1.36B-$1.385B and adjusted EBITDA $233M-$240M; Q3 revenue $335M-$345M.

$PGNYMedAI 8/10

Why Progyny (PGNY) Shares Are Sliding Today

Progyny (PGNY) shares fell about 4.5% after the fertility benefits company issued weaker guidance. Q2 revenue rose to $350.5M (+5.3% YoY) and adjusted EPS was $0.55, both above estimates. But it projected $340M revenue for the next quarter, about 3% below consensus, and cut full-year revenue to $1.37B from $1.39B.